Generate Biomedicines, Inc. (GENB) — Financial statements
Income statement, balance sheet, and cash flow for Generate Biomedicines, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | |
|---|---|---|---|
| Revenue & Gross Profit | |||
| Revenue | 32↑55.9% | 20 | |
| Cost of Revenue | 0.00 | 0.00 | |
| Gross Profit | 32↑55.9% | 20 | |
| Operating Expenses | |||
| R&D Expenses | 225↑28.2% | 175 | |
| General & Administrative Expenses | 42↑0.4% | 42 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | |
| SG&A Expenses | 42↑0.4% | 42 | |
| Other Expenses | 0.00 | 0.00 | |
| Operating Expenses | 267↑22.8% | 217 | |
| Total Costs & Expenses | 267↑22.8% | 217 | |
| Operating Results | |||
| Operating Income | -235↓19.4% | -197 | |
| Depreciation & Amortization | 13↓14.1% | 15 | |
| EBITDA | -208↓27.4% | -164 | |
| EBIT | -222↓23.8% | -179 | |
| Interest & Other Income | |||
| Net Interest Income | 13↓21.7% | 16 | |
| Interest Income | 14↓24.6% | 18 | |
| Interest Expense | 1↓46.4% | 2 | |
| Non-Operating Income | -13↑25.1% | -18 | |
| Other Income / Expenses | 12↓22.2% | 16 | |
| Income Before Tax | -223↓23.0% | -181 | |
| Income Tax Expense | 0.16↓23.1% | 0.21 | |
| Net Income & EPS | |||
| Net Income from Continuing Operations | -223↓22.9% | -181 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | |
| Net Income | -203↓16.9% | -174 | |
| Bottom-Line Net Income | -250↓16.7% | -214 | |
| EPS (Basic) | -4.98↓196.4% | -1.68 | |
| EPS (Diluted) | -4.98↓196.4% | -1.68 | |
| Weighted Average Shares | 50↓60.7% | 127 | |
| Weighted Average Diluted Shares | 50↓60.7% | 127 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.